INTRODUCTION
Haem oxygenase (HO) is the rate-limiting enzyme in haem catabolism. This enzyme cleaves haem to form biliverdin, which is converted further into bilirubin by biliverdin reductase. Bilirubin, the final product of haem catabolism by HO, has an antioxidative capacity [1] . HO activity is derived from three isoenzymes, i.e. HO-1, HO-2 and HO-3. HO-1 is the ubiquitous and inducible form, found abundantly in the spleen, placenta and fetal liver [2] [3] [4] . HO-2 is the constitutive form found mainly in the brain and testis [2] , whereas HO-3 contributes little to haem catabolism [5] .
HO-1 gene expression is activated by various types of oxidative stress, such as hydrogen peroxide, UV irradiation, cadmium chloride, sodium arsenite, menadione, buthionine sulphoximine (glutathione-depleting compound), ozone inhalation, hypoxia and hyperoxia [6] [7] [8] [9] [10] [11] . Recently we showed that the level of HO-1 mRNA increased rapidly in response to a rise in oxygen tension in human HepG2 hepatoma cells [12] . Studies on HO-1 knockout mice have proved that the up-regulation of the HO-1 gene serves as an adaptive mechanism to protect cells from oxidative damage [13] .
The hepatic expression of HO-1 mRNA is developmentally regulated [3, 4] . Hepatic HO-1 mRNA levels in human and rat are higher in the fetus than in the adult. On the other hand, rat brain HO-1 mRNA levels do not change significantly between
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moderately decreased enhancer activity. However, mutations in both regions reduced promoter activity to the basal level.
Electrophoretic mobility-shift assays demonstrated that the P5-2 fragment (k1793 to k1744) interacted with at least two nuclear factors, i.e. HNF-4 and Sp1\Sp3. Co-transfection experiments using Drosophila SL2 cells revealed that HNF-4 and Sp1\Sp3 synergistically stimulated the enhancer activity of the P5-2 fragment. These results indicate that co-operation of HNF-4 with Sp1 or Sp3 leads to the activation of hHO-1 gene expression in hepatoma cells.
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day 19 of fetal gestation and the adult [4] . The physiological significance of the higher expression of HO-1 in the fetal liver is not clear at present. However, the same pattern of fetal HO-1 gene expression in both humans and rats suggests an important function of this protein in early development and a common regulatory mechanism during development. The α-fetoprotein gene is also developmentally regulated, being expressed at a high level in the fetal liver but being dramatically repressed in the adult liver [14] . Since α-fetoprotein gene expression is high in hepatoma cells such as HepG2, the positive regulatory transfactors and cis-elements of human HO-1 (hHO-1) gene expression that function in HepG2 cells might be also active in HO-1 gene expression in the human fetus in i o. The transcription of genes that are specifically expressed in hepatic cells, such as those encoding albumin, transthyretin, α1-antitrypsin or fibrinogen, has been shown to be regulated by liver-enriched transcription factors, such as hepatocyte nuclear factor-1 (HNF-1) [15] , HNF-3 [16] , HNF-4 [17] and CCAAT\ enhancer-binding protein α (C\EBPα) [18] . We have demonstrated that the 5h-flanking region (nucleotides k1976 to k1655) of the hHO-1 gene enhanced hHO-1 promoter activity in human hepatoma HepG2 cells, but not in HeLa cells. This region carries sequences similar to HNF-1 and HNF-4 binding sites [19] . In the present study, we first defined the 50 bp enhancer element responsible for the basal expression of the hHO-1 gene. This element contains the HNF-4 binding site and confers HNF-4-mediated induction of HO-1 gene expression. Furthermore, we demonstrated that maximal promoter activity in human hepatoma cells was dependent on co-operation between the HNF-4 site and the Sp1 site, which is located downstream of the HNF-4 site.
EXPERIMENTAL

Construction of plasmids
Hybrid genes comprising the hHO-1 promoter attached to the luciferase gene were constructed as follows (see Figure 1) . Promoter fragments comprising nucleotides k58 to j24 or k263 to j24 were ligated to the pGL3-Basic vector (Promega, Madison, WI, U.S.A.) to generate phHOLUC(k58) or phHOLUC(k263) respectively [19] . phHOLUC(k58) and phHOLUC(k263) were then digested with KpnI, blunted with T4 DNA polymerase, and ligated with an EcoRV linker (CGATATCG ; Nippon Gene, Toyama, Japan) to generate phHOLUC(k58)(K\E) and phHOLUC(k263)(K\E) respectively. A pRL-TK vector (Promega) was digested with BglII and HindIII to generate a 0.8 kb fragment containing the herpes simplex virus thymidine kinase promoter. This 0.8 kb fragment was inserted into a BglII\HindIII site of the pGL3-Basic vector to generate pGL3-TK. This plasmid was digested with XhoI, blunted with T4 DNA polymerase, and ligated with an EcoRV linker (CGATATCG ; Nippon Gene) to generate pGL3-TK(X\E).
phHOLUC(k1976) [19] was digested to generate a 372 bp KpnI\BstEII fragment containing a positive regulatory region (PRR). This fragment was blunted by treatment with T4 DNA polymerase and then cloned into a SmaI site of a pGL3-
Figure 1 Cell-type-specific expression of the PRR of the hHO-1 gene on the hHO-1 and SV40 promoters
The PRR 5h-flanking fragment (positions k1976 to k1607) of the hHO-1 gene (P) was inserted upstream of two homologous hHO-1 promoters, phHOLUC(k263) (covering positions k263 to j24) and phHOLUC(k58) (covering positions k58 to j24), in the forward (j) or reverse (k) orientation. This sequence was also ligated to heterologous SV40 and herpes simplex virus thymidine kinase (TK) promoters. The reporter plasmids were used to transfect two cell lines, HepG2 and HeLa, as described in the Experimental section. After 48 h in culture, the cells were lysed and luciferase activities were determined. The luciferase activity of pGL3-Basic was designated as 1.0 for each cell line, and each value of luciferase activity represents the meanpS.E.M. for four independent experiments.
Promoter simian virus 40 (SV40) vector (Promega) and into EcoRV sites of pGL3-TK(X\E), phHOLUC(k263)(K\E) and phHOLUC(k58)(K\E), in forward and reverse orientations, to generate phHOLUCSV40\P(j), phHOLUCSV40\P(k), phHOLUCTK\P(j), phHOLUCTK\P(k), phHOLUC (k263)\P(j), phHOLUC(k263)\P(k), phHOLUC(k58)\ P(j) and phHOLUC(k58)\P(k). The unique 5h EcoRV site of phHOLUC(k58)(K\E) was used as the insertion site for various dissected DNA fragments in forward or reverse orientation to test their enhancer activity.
The expression vector for HNF-4α2 (pEF-BOS\HNF4) was generously provided by Dr M. Takiguchi [20] . Drosophila expression vectors for Sp1 and Sp3 (pPac-Sp1\flu and pPacSp3\flu respectively) were gifts from Dr J. M. Horowitz [21] , and that for Sp4 (pPac-Sp4) was from Dr G. Suske [22] . The coding region of hHNF-4α2 was amplified from pEF-BOS\HNF4 by the PCR method, then this fragment was ligated to the BamHI and XhoI sites of the pPac vector [21] to generate pPac-HNF-4α2. An internal control luciferase vector, pPac-Rluc, was constructed by replacing the Sp1 gene of the pPac-Sp1\flu vector with the Luc gene obtained from the pRL-TK vector (Promega).
Cell cultures and transient expression analysis
Dulbecco's modified Eagle's medium and minimal essential medium were purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Fetal bovine serum was obtained from Dainippon Pharmaceutical Co., Ltd (Tokyo, Japan). -Glutamine and sodium bicarbonate were from Gibco BRL (Grand Island, NY, U.S.A.). Benzylpenicillin potassium was from Meiji Seika, Ltd (Tokyo, Japan), and streptomycin was from Sigma Chemical Co. HepG2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % (v\v) fetal bovine serum, 4 mM glutamine, 250 units\ml benzylpenicillin potassium and 100 µg\ml streptomycin. HeLa cells were maintained in minimal essential medium supplemented with 10 % (v\v) fetal bovine serum, 2 mM glutamine, 250 units\ml benzylpenicillin potassium and 100 µg\ml streptomycin. Both types of cells were kept at 37 mC in CO # (5 %)\air (95 %) under a humidified atmosphere. HepG2 (1i10') and HeLa (5i10&) cells were plated in 60-mm dishes 1 day before transfection. A DNA solution containing 0.43 pmol of the test plasmid, 5 µl of FuGENE6 transfection reagent (Roche Molecular Biochemicals) and 95 µl of serum-free medium was added to the cultured cells. Cells were co-transfected with the Sea-pansy luciferase plasmid (0.1 µg) pRL-SV40 (Promega) as an internal control. After a 48 h incubation, the cells were lysed with passive lysis buffer (Promega). Cell lysates were used to determine luciferase activity with Lumat LB 9501 (EG and G Berthold, Badwildbad, Germany). A construct containing the luciferase reporter gene under the control of the SV40 promoter\enhancer (pGL3-Cont ; Promega) was used separately as a positive control. In the co-transfection assay, 1.0 µg of reporter plasmid was used for transfection, along with 0.2-2.0 µg of modulator plasmids and 0.1 µg of an internal control plasmid, pRL-SV40. The amount of modulator plasmids was adjusted to 0.42 pmol by adding empty vector, pEF-BOS. For analysis of the P5-2 mutants, the cells were transfected with 1.0 µg of reporter plasmid, 1.0 µg of modulator plasmids and 0.1 µg of pRL-SV40 as an internal control.
Drosophila SL2 cells were maintained in Schneider's medium (Invitrogen) supplemented with 10 % (v\v) fetal bovine serum under humid air at 25 mC. On the day before transfection, the SL2 cells (2.5i10&) were subcultured into 35 mm dishes. They were transfected with 0.5 µg of reporter gene, 0.05 µg of internal control vector pPac-Rluc and 0.6 µg of effector expression vectors, adjusting with empty pPac plasmid using FuGene6 solution. After 48 h, cells were harvested for luciferase assay.
Preparation of nuclear extracts
Preparation of nuclear extracts from HepG2 and HeLa cells was carried out using a modification of the protocol of Dignam et al. [23] . Protein concentrations were determined with a BCA Protein Assay Kit (Pierce).
Electrophoretic mobility-shift assay
Single-stranded oligonucleotides were end-labelled using [γ-$#P]-ATP (ICN Biochemicals, Inc., Costa Mesa, CA, U.S.A.) and T4 polynucleotide kinase, and then annealed as described previously [24] . The unincorporated label was removed by gel filtration on a Sephadex G-50 column (Amersham Pharmacia Biotech). A 10 µg aliquot of nuclear extract was incubated with 2 µg of poly(dI-dC) (Sigma) on ice for 15 min in the presence or absence of unlabelled competitor DNA (0.8 pmol), and then incubated with the end-labelled oligonucleotide (approx. 7i10$ c.p.m.\0.004 pmol) at 20 mC for 15 min. This binding reaction was carried out in a solution containing 12 mM Hepes (pH 7.9), 60 mM KCl, 4 mM MgCl # , 1 mM EDTA, 12 % glycerol, 1 mM dithiothreitol and 1i Complete TM Protease Inhibitor Cocktail (Roche Molecular Biochemicals). In the supershift experiments, 2 µl of antibody was added to the above reaction mixture, which was then incubated at 20 mC for 30 min. The reaction mixtures were loaded on to a non-denaturing 4.5 % (w\v) polyacrylamide gel (acrylamide\bisacrylamide, 29 : 1, w\w) containing 4 % glycerol made in 0.5iTBE (1iTBE contains 90 mM Tris, 89 mM boric acid and 2 mM EDTA, pH 8.0) that had been pre-electrophoresed at 130 V for 2 h at 4 mC. After electrophoresis had been performed at 150 V at 4 mC for 3 h, the gels were dried and autoradiographed with an intensifying screen.
Rabbit anti-(human Sp1) polyclonal antibody was purchased from Geneka Biotechnology Inc. 
Oligonucleotides
For the gel shift competition analysis, the oligonucleotide sequence of the δEF1 site (the κE2 sequence of the immunoglobulin κ enhancer) [25] , GTAATCTGGGCCACCTGCCTGCCTGG-GAGGA, was used. Double-stranded oligonucleotides containing the recognition sites for transcription factors HNF-4, RXR, retinoic acid receptor (RAR), peroxisome-proliferator-activated receptor (PPAR), Stat5 (signal transduction and activator of transcription 5)\Stat6, C\EBP and activator protein-1 (AP-1) were purchased from Stratagene, and the oligonucleotide for Sp1 was obtained from Geneka Biotechnology Inc. The sequences of these oligonucleotides are : HNF-4, CTCAGCTTGTACTTTG-GTACAACTA ; RXR, AGCTTCAGGTCAGAGGTCAGAG-AGCT ; RAR, TCGAGGGTAGGGTTCACCGAAAGTTCA-CTCG ; PPAR, CAAAACTAGGTCAAAGGTCA ; Stat5\ Stat6, GTATTTCCCAGAAAAGGAAC ; C\EBP, TGCAG-ATTGCGCAATCTGCA ; AP-1, CGCTTGATGACTCAGC-CGGAA ; Sp1, ATTCGATCGGGGCGGGGCGAGC. The sequences of the oligonucleotides for plasmid constructions and the electrophoretic mobility-shift assay were as follows : P5-1 ( positions k1807 to k1769), TGGGGGACTTTATCTGCC-TAGGACAACCTTTGTCCCTGT ; P5-2 (positions k1793 to k1744), TGCCTAGGACAACCTTTGTCCCTGTGCGG-CTCCACCTCCACCTTCCCTTA ; P5-3 (positions k1768 to k1724), GCGGCTCCACCTCCACCTTCCCTTAAAGTCG-GCCTTTCACCTCCA [19] .
RESULTS
Cell-type-specific expression of the hHO-1 gene on the hHO-1 and SV40 promoters
To examine the cell-type specificity of the PRR [19] of the hHO-1 gene in detail, we introduced the constructs shown in Figure 1 into HepG2 and HeLa cells for transient expression. In HepG2 cells, insertion of the PRR upstream of the homologous promoter (k58 to j24) of phHOLUC(k58) in the forward (j) and reverse (k) orientations resulted in 9-fold and 4.6-fold increases respectively in luciferase activity. The insertion of this fragment upstream of the other homologous promoter (k263 to j24) of phHOLUC(k263) increased luciferase activity by only 1.9-fold (forward) and 2.1-fold (reverse), although the absolute luciferase activities were comparable between these promoter constructs. Furthermore, insertion of the PRR upstream of the heterologous SV40 promoter in the forward and reverse orientations resulted in 3.7-and 4.6-fold increases respectively in luciferase activity in HepG2 cells. When the PRR was inserted upstream of the thymidine kinase promoter, the increase in luciferase activity was slight. In contrast with the results in HepG2 cells, no significant activation by the PRR was observed in HeLa cells. These results indicate that the PRR exerts its effect in a cell-type-dependent
Figure 2 Localization of the core regulatory region within the PRR that confers enhancer activity
(A) Schematic representation of the hHO-1 gene PRR and deletion constructs. The PRR was divided into six fragments, P1 (k1976 to k1829), P2 (k1831 to k1607), P3 (k1976 to 1905), P4 (k1905 to k1807), P5 (k1807 to k1724) and P6 (k1724 to k1607), with restriction enzymes, and cloned upstream of the hHO-1 promoter (positions k58 to j24) and the luciferase hybrid vector, phHOLUC(k58), in the forward (j) or reverse (k) orientation. The DNA sequences that resemble transcription factor elements are indicated as AP-1, HNF-4, Sp1, δEF1, STAT-X, c-Rel, HNF-1 and GATA-X, which denote the binding sites for AP-1, HNF-4, Sp1, δEF1, STAT signalling transcription factors, c-Rel, HNF-1 and GATA transcription factors respectively. NRE BOX3 denotes the sequence homologous to silencer elements of the chicken lysozyme gene. (B) Functional analysis of the PRR. The reporter plasmids were transfected into two cell lines, HepG2 and HeLa, and luciferase activities were determined as described in the Experimental section. The luciferase activity of pGL3-Basic was designated as 1.0 for each cell line, and each value of luciferase activity represents the meanpS.E.M. for four independent experiments. manner, and that the activity of the PRR depends on promoter sequences.
Identification of the core regulatory region within the PRR that confers cell specificity
To localize the core regulatory region within the PRR fragment, we divided the PRR into six fragments, i.e. P1, P2, P3, P4, P5 and P6, using restriction enzymes as shown in Figure 2 (A), and cloned them upstream of the hHO-1 promoter (positions k58 to j24) of phHOLUC(k58) in the forward or reverse orientation. We employed the region encompassing positions k58 to j24 as the test promoter in this assay, since the PRR strongly activated phHOLUC(k58) by up to 9-fold (Figure 1 ), in contrast with the weaker 2.1-fold enhancement of phHOLUC(k263). HepG2 and HeLa cells were transfected with each test plasmid, and luciferase activities were then measured ( Figure 2B ). In HepG2 cells, the full enhancer activity of the PRR resided in the P2 fragment (10-fold increase). Further dissection showed that nearly comparable activity resided in the P5 fragment, the activity of which was HNF-4 regulation of the haem oxygenase-1 gene The P5 fragment was divided into three fragments, P5-1 (k1807 to k1769), P5-2 (k1793 to k1744) and P5-3 (k1768 to k1724), and cloned upstream of the hHO-1 promoter (positions k58 to j24) in phHOLUC(k58). HepG2 cells were transfected with reporter plasmids, and luciferase activities were determined as described in the Experimental section. The luciferase activity of phHOLUC(k58) was designated as 1.0, and each value of luciferase activity represents the meanpS.E.M. for four independent experiments.
Figure 4 Identification of the core regulatory region within the P5-2 fragment containing the cis-regulatory element that confers enhancer activity
(A) Nucleotide sequence of the P5-2 fragment. The DNA sequences that resemble transcription factor elements are indicated as HNF-4, Sp1, δEF1 and STAT-X. The P5-2 fragment was divided into two overlapping fragments, P5-2D3 and P5-2D5, representing deletion of the 3h-end and the 5h-end respectively. (B) Functional analysis of the P5-2 fragment. The reporter plasmids were used to transfect HepG2 cells, and luciferase activities were determined as described in the Experimental section. The luciferase activity of phHOLUC(k58) was designated as 1.0, and each value of luciferase activity represents the meanpS.E.M. for four independent experiments. approx. 79 % that of the P2 fragment when located in a forward orientation in relation to the hHO-1 promoter. The P2 fragment displayed high activity (23-fold activation) when inserted in the reverse orientation. The P4 and P6 fragments showed greater activation in the reverse than in the forward orientation. These results indicate that the P5 fragment contains mainly positive elements. Surprisingly, when HeLa cells were transfected with these plasmids, although the P2 fragment did not activate the HO-1 promoter, the P5 fragment was able to activate the HO-1 promoter to an extent comparable with that in HepG2 cells (5.5-fold). This may result from unidentified negative regulatory elements that potentially act only in HeLa cells.
In order to localize the positive regulatory element within the P5 fragment, we segmented P5 into three overlapping fragments, i.e. P5-1, P5-2 and P5-3. These fragments were ligated upstream of the HO-1 promoter of phHOLUC(k58), to generate phHOLUC(k58)\P5-1, phHOLUC(k58)\P5-2 and phHOLUC(k58)\P5-3, as shown in Figure 3 . The positive regulatory activities of these vectors were assayed in HepG2 cells. The activity of the P5-2 fragment was comparable with that of the original P5 fragment, while those of P5-1 and P5-3 were less than half of the activity of P5.
Consequently, the P5-2 fragment was dissected further into two overlapping fragements, P5-2D3 and P5-2D5, which are 3h and 5h end-deletion products respectively of the parental P5-2 fragment ( Figure 4A ). The promoter activities of P5-2D3 and P5-2D5 were approximately half that of P5-2, in both orientations ( Figure 4B ). These results indicate that the core PRR is localized primarily in the P5-2 fragment, and that full activity of the PRR requires both the 5h-and 3h-regions of the P5-2 fragment.
Inspection of the sequence of P5-2 using TFSEARCH [26] revealed that this region contains several putative binding sites for a number of known transcription factors, such as HNF-4, Sp1, δEF1 and STAT-X ( Figure 4A ). To define further the core sequences within the P5-2 fragment, we synthesized a series of
Figure 6 Gel shift competition analysis using P5-2 and its mutants
Nuclear extract of HepG2 cells (10 µg) was incubated with 0.004 pmol of 32 P-labelled probes : P5-2 (A), P5-2D3 (B) and P5-2D5 (C). In a competition assay, a 200-fold molar excess of unlabelled competitors was added to the reaction mixture. Lane 1 contains no extract. Lane 2 shows the binding of the HepG2 nuclear factors to the 32 P-labelled wild-type P5-2, P5-2D3 or P5-2D5 fragment without competitor. Lanes 3-8 show competition of nuclear factor binding by a 200-fold molar excess of unlabelled mutant oligonucleotides (M1-M5). Lanes 9-11 show competition with unlabelled probes P5-2D3, P5-2D5 and P6-3 (unrelated sequence in the 5h-upstream region of the hHO-1 gene ; k1712 to k1687) respectively. The resulting complexes were resolved by electrophoresis in non-denaturing 4.5 % (w/v) polyacrylamide gels. Arrowheads indicate novel DNA-protein complexes.
base-substitution mutants of this fragment ( Figure 5A ), and examined their effects on hHO-1 promoter activity ( Figure 5B) . Mutations in the HNF-4 site (k1777 to k1772 ; mutant M3 in Figure 5A ) reduced promoter activity to a level lower than that observed for wild-type P5-2. Mutations in the Sp1 site (k1761 to k1752 ; M5) resulted in an even greater decrease in promoter activity. Mutations in the region k1770 to k1766 (M4) had a weaker effect on promoter activity than mutants M3 or M5. The HNF-4 regulation of the haem oxygenase-1 gene base-substitution mutants (M3, M4 and M5) moderately reduced the HO-1 promoter activity. This prompted us to test whether these authentic sequences co-operate to activate gene expression. When a double mutation was introduced into the P5-2 fragment (mutant M6), enhancer activity was reduced to the basal level shown by the minimal promoter construct phHOLUC(k58) ( Figure 5C ).
Gel shift competition analysis of factors binding to P5-2, P5-2D3 and P5-2D5 fragments
To identify nuclear factors that bind to the regulatory elements in the P5-2 fragment, we performed gel shift analysis using endlabelled P5-2 ( Figure 6A ), P5-2D3 ( Figure 6B ) and P5-2D5 ( Figure 6C ) fragments as probes. Incubation of the probes with nuclear extracts prepared from HepG2 cells produced at least five DNA-nuclear-factor complexes (I-V ; Figure 6 , lane 2). These complexes represented sequence-specific interactions of nuclear factors with the P5-2, P5-2D3 and P5-2D5 fragments, since an excess (200i) of unlabelled P5-2 (lane 3), P5-2D3 (lane 9) or P5-2D5 (lane 10) fragments competed with the probes, whereas an unrelated fragment [P6-3, which is located in the 5h-upstream region of the hHO-1 promoter (k1712 to k1687) ; lane 11] did not compete with P5-2 and its deletion probes.
Next, we tested whether the binding of nuclear factors to the P5-2, P5-2D3 and P5-2D5 fragments would correlate with transcriptional activation. For this purpose, P5-2 mutant sequences were examined as competitors for the binding of nuclear factors to the P5-2, P5-2D3 and P5-2D5 fragments in the gel shift assay ( Figure 6, lanes 4-8) . When P5-2D3 was used as a labelled probe, mutants M2 and M3 failed to compete for the formation of DNA-nuclear-factor complexes III and IV. This result indicates that the M2 and M3 regions are critical for the binding of nuclear factors to the P5-2D3 fragment, although the M2 and M3 mutants showed moderately reduced enhancer activity compared with the wild-type sequence, as shown in Figure 5 . When we used P5-2D5 as a probe, only mutant M5 showed impaired binding of nuclear factors. This loss of competition of M5 was comparable with the reduced transcription activity observed in Figure 5 . As for the M4 mutant, although this mutation did not have any retarding effects on the formation of DNA-nuclear-factor complexes, it resulted in moderately reduced transcriptional activity compared with the wild-type sequence, suggesting that the M4 mutation could affect productive trans-factor binding to cis-DNA elements or proteinprotein interactions in i o, but such effects could not be detected using an in itro gel shift competition assay. These results indicate that nuclear factors in complexes III and IV bind to the HNF-4 site, and those in complexes I, II and V bind to the Sp1 site.
Binding of HNF-4 and Sp1/Sp3 to the PRR of the HO-1 gene
To characterize the factors that bind to the P5-2 fragment, we carried out gel shift competition analysis using double-stranded oligonucleotides containing binding sites for HNF-4, RXR, RAR, PPAR, Stat5\Stat6, δEF1, AP-1 and C\EBP (Figure 7) , and Sp1 (Figure 8 ). The P5-2 fragment contains sequences equivalent to binding sites for HNF-4, Sp1, Stat5\Stat6 and δEF1 ( Figure 4A ). When the P5-2D3 fragment was used as a DNA probe, the HNF-4-binding oligonucleotide efficiently competed with the probe for the formation of complex IV ( Figure 7B , lane 4). When the P5-2 fragment was used as a DNA probe, the competition with the HNF-4 oligonucleotide apparently reduced the formation of complex IV ( Figure 7A, lane 4) . Since it has been demonstrated that one nuclear receptor-binding sequence shows cross-reactivity with those for other different nuclear receptors [27] , oligonucleotides with which the nuclear receptors RXR, RAR and PPAR associate were tested as competitors. RXR, RAR and PPAR oligonucleotides competed with the P5-2 and P5-2D3 probes, although their affinities for the nuclear
Figure 8 Gel shift analysis of P5-2 and its deletion fragments using Sp1 competitor and Sp-family antibodies
Nuclear extract of HepG2 cells (10 µg) was incubated with 0.004 pmol of 32 P-labelled probes : P5-2 (A), P5-2D3 (B) and P5-2D5 (C). In a competition assay, a 200-fold molar excess of unlabelled P5-2, P5-2D3 or P5-2D5 fragment (' self ' ; lane 3), P6-3 (unrelated sequence in the 5h-upstream region of the hHO-1 gene ; lane 7) or Sp1 double-stranded oligonucleotide containing the binding site for the Sp transcription factor (lane 4) was added to the reaction mixture. In a supershift assay, nuclear extracts were incubated with the 32 P-labelled P5-2, P5-2D3 or P5-2D5 probe alone (lanes 2 and 9) or with preimmune serum (PI rabbit ; lanes 6 and 10) or antibodies against Sp1 (lanes 5 and 11), Sp2 (lane 12), Sp3 (lane 13) or Sp4 (lane 14). The resulting complexes were resolved by electrophoresis in non-denaturing 4.5 % (w/v) polyacrylamide gels. Lanes 1 and 8 contain no extract. Arrowheads indicate novel DNA-protein complexes. The stars indicate novel complexes of reduced mobility generated in the presence of anti-Sp-family antibodies.
factors in complexes III and IV seemed to be different from each other ( Figures 7A and 7B, lanes 5-7) . When the P5-2D5 fragment was used as a DNA probe, only the Sp1 oligonucleotide competed with the probe for the formation of the nuclear-factor-DNA complexes ( Figure 8C, lane 4) . Addition of the unlabelled Sp1 oligonucleotide (100i) to the assay clearly competed with the P5-2 probe for formation of the retarding complex ( Figure 8A , lane 4), concomitant with an enhanced HNF-4 shift. The oligonucleotides for Stat5\Stat6, δEF1, AP-1 (the ubiquitous factor), C\EBP (the typical liver-enriched factor) and P6-3 (an unrelated oligonucleotide) failed to block the formation of the complexes (Figure 7, lanes 7-9) .
To further characterize nuclear factor binding to the P5-2 fragment, we performed a supershift assay using antibodies against HNF-4α, COUP-TFI, ARP-1 (COUP-TFII), RXR and RAR (Figure 9 ), and Sp1, Sp2, Sp3 and Sp4 (Figure 8) . The anti-HNF-4α antibody supershifted complex IV with the probes P5-2 and P5-2D3, but not with the P5-2D5 probe ( Figure 9, lane 5) . Antibodies against Sp1 and Sp3 also interacted with the retarding complex I with the DNA probes P5-2 and P5-2D5, but not with P5-D3 (Figure 8, lanes 5 and 11) . Anti-Sp3 antibody supershifted complexes II and V with the DNA probes P5-2 and P5-2D5, but not with P5-D3 (Figure 8, lane 13) . Anti-Sp4 antibody interacted with the retarded band with the P5-2D3 DNA probe ( Figure 8B , HNF-4 regulation of the haem oxygenase-1 gene 
Synergistic activation of the HO-1 promoter by HNF-4 and Sp1/Sp3
The reporter gene assay and supershift analysis demonstrated the binding of HNF-4, Sp1 and Sp3 to the HO-1 promoter. To obtain further insight into the actions of HNF-4 and Sp1\Sp3 on HO-1 gene expression, we performed co-transfection experiments using HepG2 cells and Drosophila Schneider SL2 cells. SL2 cells were used because they show no endogenous expression of Sp1 and Sp3. When HepG2 cells were co-transfected with the HNF-
Figure 10 Activation of the hHO-1 promoter by HNF-4 in a co-transfection assay
HepG2 cells were co-transfected with various amounts of the HNF-4α2 expression plasmid pEF-BOS/HNF-4 and 1.0 µg of the reporter plasmid phHOLUC(k58)/P5-2(j) containing the hHO-1(k58) promoter. Luciferase activities were determined as described in the Experimental section. The activity of the control expression vector pEF-BOS was designated as 1.0, and each value of luciferase activity represents the meanpS.E.M. for four independent experiments. 4α2 expression vector and the P5-2 Luc reporter, promoter activity was enhanced in a dose-dependent manner, reaching up to 2.5-fold increased expression ( Figure 10 ). However, the mutant promoter\reporter, P5-2 M6 Luc ( Figure 5 ), was not activated by co-transfection with the HNF-4α2 expression vector (results not shown).
Synergistic effects of Sp1\Sp3 and HNF-4α2 were demonstrated using SL2 cells (Figure 11 ). The P5-2 reporter was cotransfected into SL2 cells with Sp1\Sp3 and HNF-4α2 expression vectors, alone or in combination. Co-transfection of the reporter with the HNF-4α2 expression vector alone resulted in an approx. 
DISCUSSION
In recent years, a number of studies have been published on the HO-1 gene promoter. HO-1 gene expression is activated by stresses, such as heat shock, heavy metals, UV irradiation, lipopolysaccharide, hypoxia and hyperoxia, and the elements responsive to these stresses have been identified [28] . The stressinduced activation of the HO-1 gene is mediated through heat-shock elements [29] , hypoxia-response elements [9] , stressresponse elements [30] and cadmium-responsive elements [31] . Many physiological and environmental stresses have been shown to induce HO-1 gene expression via the stress-response element, to which nuclear factor-E2-related factors bind [32] . HO-1-deficient cell lines are hypersensitive to oxidative stress induced by sub-lethal levels of hemin and H # O # . HO-1 knockout mice, having no HO-1 activity, are not resistant to a sub-lethal lipopolysaccharide injection [13] . This indicates that HO-1 activity is very important in defence against the oxidative burden. It has also been proposed that a polymorphic DNA sequence of
Figure 11 Synergistic activation of the hHO-1 promoter by HNF-4 and Sp1/Sp3
Drosophila SL2 cells were transfected with the reporter plasmid phHOLUC(k58)/P5-2(j) containing the hHO-1(k58) promoter and with Sp1, Sp3, Sp4 and HNF-4α2 expression vectors (pPac-Sp1, pPac-Sp3, pPac-Sp4 and pPac-HNF-4α2 respectively), alone or in combination as indicated. Luciferase activities were determined as described in the Experimental section. The activity of the control expression vector pPac was designated as 1.0, and each value of luciferase (LUC) activity represents the meanpS.E.M. for four independent experiments. the HO-1 promoter can modulate the degree of vulnerability to stress. A positive correlation between the length of the (GT) n repeat in the HO-1 promoter and susceptibility to the development of chronic pulmonary emphysema has been reported [33] . The long (GT) n repeat could attenuate the HO-1 expression that may be induced by reactive oxygen species in cigarettes, thereby resulting in the development of chronic pulmonary emphysema. The PRR in the HO-1 gene exhibited strong enhancer activity (9-fold activation) in the context of a minimal HO-1 promoter (positions k58 to j24) which did not contain the (GT) n repeat ; in contrast, only low activity was observed with a (GT) n -repeat-containing larger HO-1 promoter (k263 to j24) (Figure 1 ). This promoter dependency of the enhancer activity of the PRR may be partly attributable to the (GT) n repeat.
In the present study, deletion analysis of the cell type-specific promoter of the hHO-1 gene identified the HNF-4 binding site in the 5h-flanking region. This direct repeat (5h-CAACCTTTGT-CCC-3h) is the consensus DNA sequence for HNF-4 binding [34] . Mutations at this site resulted in a partial reduction in the basal expression level of the gene. Similar phenomena were also observed for coagulation factor VII and the hepatic CYP2D6 gene promoters [35] [36] [37] . This moderate reduction in basal expression caused by the M2 mutation was extended to full reduction by an additional mutation at the M5 site, whereas the M5 mutation alone caused only half reduction. The same reducing effect of a single mutation at the M2 or M5 site was demonstrated in the HNF-4 cotransfection experiments (data not shown). On the other hand, gel shift analysis revealed that the mutations in the HNF-4 site (M2 and M3) abolished the binding capacity for trans-acting factors. These contradictory results obtained from transfection experiments and gel shift assays imply that the binding affinity between M2 or M3 mutant and DNA-binding factors may be so weak that the each mutant does not efficiently compete with the wild-type sequence in the gel shift analysis. But these affinities could be strong enough to promote transcription in the reporter gene assay.
HNF-4 plays a critical role in the tissue-specific and hypoxiainducible expression of the erythropoietin gene, whereas COUP-TF has a negative modulatory role [38] . Expression of HNF-4 in HeLa cells enhanced the hypoxic induction of an erythropoietin gene reporter, and mutation of the HNF-4 site diminished HNF-4 enhancement of the hypoxic response in HeLa cells from approx. 11-fold to 3-fold [38] . Hypoxia is known to induce HO-1 gene expression via a hypoxia-response element that is located approx. 8 kbp upstream of the hHO-1 gene and is bound by hypoxia-inducible factor-1 (HIF-1), although the physiological significance of the hypoxic induction of the HO-1 gene is not clearly understood [9] . Hypoxia in i o also induces HO-1 expression in rat tissues. A marked increase in the HO-1 mRNA level was observed in the lung, liver, heart and aorta. Hypoxic induction in the liver is greater than in other tissues [9] . This high responsiveness in the liver might be due to the co-expression and association of HIF-1 and HNF-4 in hepatic cells under hypoxic conditions.
Expression of the HO-1 gene is developmentally regulated. The level of mRNA for HO-1 in the rat liver is higher in the fetus than in the adult. In the human fetal liver, the enzyme activity was 8 times higher than that detected in the adult liver [3, 4] . The HO-1 mRNA level in the placenta was comparable with that in the spleen, the major organ for HO-1 synthesis in the adult [4] . These changes seem to occur in response to the hypoxic environment that is maintained in the fetus. Taken together with the finding that cells overexpressing HO-1 exhibited remarkable resistance to high oxygen toxicity [9] , these results suggest that the high-level expression of antioxidative HO-1 at late gestation may function in protection of the newborn against the sudden oxygen surge after birth.
Sp1 is a sequence-specific DNA-binding protein that plays a role in the transcription of many genes that contain a GC or GT box (KRGGMGKRRY) in their promoters [39, 40] . Additional members of the Sp gene family, i.e. Sp2, Sp3 and Sp4, have been identified, and they all have a highly conserved zinc-finger DNAbinding domain [41] . Sp1, Sp3 and Sp4 can all bind to the same recognition sequences. Sp1 and Sp3 are ubiquitous factors, but Sp4 is expressed mainly in neural cells. This expression profile is consistent with our results showing the interaction of Sp1 and Sp3 with the P5-2 fragment of the HO-1 gene in HepG2 cells (Figure 8 ). Double transfection of Sp1 and HNF-4 into Drosophila SL2 cells resulted in synergistic activation of the P5-2-derived HO-1 gene promoter. Sp3 transfection also activated HO-1 transcription synergistically with HNF-4 ( Figure 11 ). In contrast, transcriptional repression of Sp3 has been reported in several genes using various types of cells [42, 43] . Therefore these results suggest that roles of Sp3 in transcription may depend on the cellular context.
Synergism of HNF-4 and Sp1\Sp3 in up-regulating HO-1 gene expression was demonstrated in SL2 cells. Co-ordination of HNF-4 regulation of the haem oxygenase-1 gene HNF-4 and Sp1 has been reported in apolipoprotein CIII gene expression [44, 45] . The molecular mechanism behind the synergistic up-regulation of target genes by HNF-4 and Sp1\Sp3 is unclear. It has been demonstrated that a co-activator, CREB (' cAMP-response-element-binding protein ') binding protein (CBP), stimulated interaction of Sp1 with the target DNA, whereas DNA binding by Sp1 inhibited the interaction of Sp1 with CBP [46] . HNF-4 and Sp1 were shown to stimulate the histone acetyltransferase activity of CBP [47] . Moreover, acetylated HNF-4 also showed higher affinity for the target DNA than the unacetylated protein [48] . Studies are ongoing in our laboratory to determine the interaction of HNF-4 and Sp1\Sp3 proteins, and the role of acetylation of these transcription factors, in HO-1 gene expression.
In conclusion, we have identified the cell-type-dependent positive regulatory region of the hHO-1 gene and have localized its core elements to which a cell-type specific factor, HNF-4, and general transcription factors, Sp1\Sp3, bind. Furthermore, cooperation between HNF-4 and Sp1\Sp3 induces synergistic transcriptional activation of the hHO-1 gene promoter in SL2 cells. The physiological function and detailed mechanism of the co-operation between HNF-4 and Sp1\Sp3 in gene expression will be investigated in future studies. Moreover, studies on the regulatory elements of the HO-1 gene and identification of the individual sequence patterns of these elements should be applicable to protection against diseases caused by physiological and environmental oxidative stresses.
